JASMINE DORISE JOSEPH PA
Prescription History 1407428188
Physician Assistant - Medical in Duluth, GA

NPI Status: Active since July 13, 2021

Contact Information

3790 PLEASANT HILL RD STE 170
DULUTH, GA
ZIP 30096
Phone: (707) 360-1020

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JASMINE DORISE JOSEPH PA, an active Medical specialist practicing in Duluth, GA. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 25 documented patient claims. Among these therapy options, the most frequently utilized medication is Genvoya, which accounts for 13 claims alone.

Medication Index

No matching medications currently found on file.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
GA State Average Benchmarks
Peer Average Claims94.0
Peer Average 30-Day Fills98.1
Peer Average Days Supply2,936
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.2% less volume than the regional standard for practitioners inside GA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $49,121.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,093.49

State Avg Cost Per Claim

$3,969.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Genvoya

Generic Formulation: Elviteg/Cob/Emtri/Tenof AlafenSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
GA State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills51.8
Peer Average Days Supply1,546
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.0% less volume than the regional standard for practitioners inside GA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $53,741.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,133.97

State Avg Cost Per Claim

$3,883.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS.

Therapeutic Applications

This product is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Elvitegravir is known as an integrase inhibitor. Cobicistat helps elvitegravir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor; both kinds of drugs are often called NRTIs. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JASMINE DORISE JOSEPH PA provides transparency into local medical care patterns within Duluth, GA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.